Ribera JM, et al. - Since recurrence of disease occurs in 20% to 40% of adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) treated with chemotherapy and tyrosine kinase inhibitors (TKIs), researchers reported the incidence, treatment, and outcome following first disease recurrence in young and older adults treated in the ALL Ph08 trial. Findings revealed that the most common mutation noted at the time of disease recurrence was T315I. In young and older adults with Ph+ ALL who were treated with imatinib and hematopoietic stem cell transplantation chemotherapy, recurrence of disease was frequent. While most patients responded to rescue therapy, their results were poor, particularly with regard to the recurrence of overt disease.